Loading
Latest filing published 10 Aug 2026 for Corbus Pharmaceuticals Holdings, Inc., €105k.
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Sean F. Moran is a declared insider at 3 companies (finance chief); the most frequent names are Corbus Pharmaceuticals Holdings, Inc., Invivo Therapeutics Holdings Corp. and Imunon, Inc. Between 8 December 2008 and 7 August 2026, the trades on record add up to 82 filings.
The open-market side counts 55 purchases for €1.1M alongside 13 sales for €1.4M. Taken together, the sales exceed the purchases by €302k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 5 share grants and 9 option exercises. In 2026 alone, the filings show no purchases and 2 sales.
Half of the purchases are above €3,577 and half below. Clusters matter here: 14 out of 18 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The record was last updated on 10 August 2026 with an open-market sale (€105k) in Corbus Pharmaceuticals Holdings, Inc. The most recent open-market purchase was published on 10 August 2022, 1,536 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations